줄기세포 치료 시장 - 예측(2026-2031년)

Global Stem Cell Therapy Market, with a 17.81% CAGR, is projected to increase from USD 392.506 million in 2025 to USD 1049.353 million in 2031.

The stem cell therapy market is a high-potential segment within regenerative medicine, focused on the development and commercialization of therapeutic interventions using stem cells to repair, replace, or regenerate damaged cells and tissues. This market encompasses a spectrum of approaches, including autologous therapies (using a patient's own cells), allogeneic therapies (using donor-derived cells), and induced pluripotent stem cell (iPSC)-derived products. It targets a wide array of debilitating conditions, primarily in areas of high unmet medical need where conventional treatments are inadequate, such as certain autoimmune, inflammatory, degenerative, and ischemic diseases.

Market expansion is fundamentally driven by the convergence of advancing science, demographic shifts, and significant unmet clinical needs. A primary catalyst is the robust and expanding pipeline of clinical trials across numerous therapeutic areas. These trials are essential for generating the clinical evidence required to validate safety, efficacy, and therapeutic mechanisms, moving stem cell therapies from experimental concepts toward approved, reimbursable treatments. The increasing volume and scope of these trials reflect sustained investment and a maturing scientific foundation.

Concurrently, a powerful demographic driver is the global growth of the aging population. Aging is a primary risk factor for a host of degenerative and chronic conditions-such as osteoarthritis, cardiovascular disease, and neurological disorders-that are potential targets for regenerative approaches. The rising prevalence and associated economic burden of these age-related diseases create a compelling need for novel therapeutic paradigms that can restore function rather than merely manage symptoms, positioning stem cell therapy as a strategically important future modality.

A critical enabler of this growth is the substantial and increasing investment in stem cell research and development from both public and private sectors. This funding supports foundational science, process development for scalable and consistent cell manufacturing, and the costly clinical trial programs necessary for regulatory approval. This financial commitment is a key indicator of the long-term strategic importance ascribed to the field.

Strategic collaborations and partnerships constitute another dominant trend shaping the market. The complexity of developing a cell therapy-spanning biology, manufacturing, clinical development, and commercialization-often exceeds the capabilities of any single entity. Consequently, partnerships between biotechnology innovators, large pharmaceutical companies, and academic research institutions are commonplace. These alliances combine scientific expertise with regulatory experience, manufacturing scale, and commercial reach, de-risking development and accelerating the path to market.

Geographically, North America is established as the leading market, characterized by a concentration of leading research institutions, a high volume of clinical trial activity, a sophisticated venture capital ecosystem, and a regulatory framework (through the FDA) that has established pathways for cell therapy approval. The region's well-funded healthcare system and early adoption of innovative therapies further solidify its leadership position.

The competitive landscape is bifurcated between a few commercially approved products (in specific indications like graft-versus-host disease) and a broad, diverse field of clinical-stage biotechnology companies. Competition centers on demonstrating definitive clinical efficacy, achieving robust and reproducible cell manufacturing, securing intellectual property around specific cell types or differentiation protocols, and navigating complex regulatory and reimbursement landscapes. Success hinges on translating promising preclinical data into clear, pivotal clinical trial outcomes.

Despite its transformative potential, the market faces profound scientific, regulatory, and commercial challenges. The foremost hurdle remains the need for unequivocal clinical proof of efficacy in large, well-controlled trials for complex diseases. The biological mechanisms are intricate, and patient responses can be variable. Furthermore, the path to commercialization is exceptionally costly and complex, involving mastering logistically challenging cell harvesting, processing, and delivery, while simultaneously establishing reimbursement models for high-cost, potentially curative one-time therapies.

In conclusion, the stem cell therapy market represents a frontier of medical innovation with the potential to address fundamental causes of disease. Its growth is supported by compelling demographic and clinical needs, but its trajectory is contingent on overcoming significant technical and commercial validation hurdles. For industry experts, strategic focus must center on generating rigorous clinical data, solving scalable and automated manufacturing challenges, and building viable commercial and access models. The future will likely involve more targeted, next-generation engineered cell products and combination approaches. Success in this market will be defined not by the promise of the technology, but by the consistent ability to deliver safe, effective, and accessible therapies that demonstrably alter disease progression and improve patient lives, thereby justifying their place in future treatment arsenals.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Global Stem Cell Therapy Market Segmentation

• By Type
• Allogenic
• Autologous
• By Application
• Musculoskeletal Disorder
• Neurological Disorder
• Cardiovascular Disease
• Oncology
• Others
• By End-User
• Hospitals
• Specialty Clinics
• Research & Academic Institute
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations
• 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL STEM CELL THERAPY MARKET BY TYPE

• 5.1. Introduction
• 5.2. Allogenic
• 5.3. Autologous

6. GLOBAL STEM CELL THERAPY MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Musculoskeletal Disorder
• 6.3. Neurological Disorder
• 6.4. Cardiovascular Disease
• 6.5. Oncology
• 6.6. Others

7. GLOBAL STEM CELL THERAPY MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Specialty Clinics
• 7.4. Research & Academic Institute
• 7.5. Others

8. GLOBAL STEM CELL THERAPY MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Vericel Corporation
• 10.2. Globus Medical Inc.
• 10.3. Athersys, Inc.
• 10.4. Bristol-Myers Squibb Company
• 10.5. Jcr Pharmaceuticals Co., Ltd.
• 10.6. Anterogen Co., Ltd.
• 10.7. Takeda Pharmaceutical Company Limited
• 10.8. Fate Therapeutics
• 10.9. Gilead Sciences, Inc.
• 10.10. Mesoblast Ltd
• 10.11. Pharmicell Inc.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations